CTLT * Stock Overview Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Catalent, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Catalent Historical stock prices Current Share Price US$1,020.00 52 Week High US$1,020.00 52 Week Low US$1,020.00 Beta 1.16 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change 6.77% Change since IPO -7.70%
Recent News & Updates
Catalent, Inc.(NYSE:CTLT) dropped from S&P 500 Value Dec 23
Catalent, Inc.(NYSE:CTLT) dropped from FTSE All-World Index (USD) Dec 20 Catalent, Inc Announces Board Changes Novo Holdings A/S completed the acquisition of Catalent, Inc. (NYSE:CTLT) from a group of shareholders. Dec 18
Catalent, Inc. announced delayed annual 10-K filing Aug 31
Insider recently sold Mex$4.4m worth of stock Aug 10 See more updates
Catalent, Inc.(NYSE:CTLT) dropped from S&P 500 Value Dec 23
Catalent, Inc.(NYSE:CTLT) dropped from FTSE All-World Index (USD) Dec 20 Catalent, Inc Announces Board Changes Novo Holdings A/S completed the acquisition of Catalent, Inc. (NYSE:CTLT) from a group of shareholders. Dec 18
Catalent, Inc. announced delayed annual 10-K filing Aug 31
Insider recently sold Mex$4.4m worth of stock Aug 10
President recently sold Mex$10.0m worth of stock Aug 01
Insufficient new directors Jul 26 Catalent, Inc. announced delayed 10-Q filing Feb 13
Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million. Feb 06
Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million. Feb 05
Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024 Jan 27
Catalent, Inc. Announces Executive Changes Jan 17
Catalent, Inc., Annual General Meeting, Jan 25, 2024 Dec 16 Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024
Catalent, Inc. announced delayed 10-Q filing Nov 14
Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023 Nov 01
Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023 Sep 19
Catalent Receives NYSE Notice Regarding Late Form 10-K Filing Sep 16
Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors Sep 12
Catalent, Inc. announced delayed annual 10-K filing Sep 01
Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022) Aug 31 Catalent, Inc. Announces Board Changes
President recently sold Mex$1.6m worth of stock Aug 30
Insufficient new directors Aug 30
Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023 Aug 24
Catalent, Inc. Announces Executive Changes Aug 02
Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index Jun 25 Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023
Catalent Regains Compliance with NYSE Continued Listing Standards Jun 14 Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023
New minor risk - Earnings quality Jun 13 Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023
Catalent, Inc. announced delayed 10-Q filing May 12
Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023 May 09
Insider recently sold Mex$1.3m worth of stock May 05
Investor sentiment deteriorates as stock falls 36% Apr 18
Investor sentiment improves as stock rises 50% Mar 03
Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary Feb 14
Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023 Feb 08
Danaher Reportedly Expresses Takeover Interest in Catalent Feb 07
Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023 Jan 21
Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America Jan 18
Catalent, Inc. Announces Director Changes Dec 20
Insider recently sold Mex$796k worth of stock Dec 08
Investor sentiment improved over the past week Dec 01
Investor sentiment deteriorated over the past week Nov 08
Insider recently sold Mex$3.2m worth of stock Nov 04
First quarter 2023 earnings released Nov 03
Catalent, Inc. Revises Revenue Guidance for the Full Year 2023 Nov 02
Now 22% undervalued Nov 02
Investor sentiment deteriorated over the past week Oct 25
Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022 Oct 18
Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million. Oct 05
Investor sentiment deteriorated over the past week Oct 04
Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer Sep 20
Catalent, Inc., Annual General Meeting, Oct 27, 2022 Sep 17 Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022
Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021) Aug 29
Executive Chair of the Board recently sold Mex$80m worth of stock Aug 28
Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million. Aug 11
Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022 Aug 06 Catalent, Inc. Announces Board Changes
Insider recently sold Mex$251k worth of stock Jun 17
Insider recently sold Mex$251k worth of stock Jun 14
Insufficient new directors May 30
Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022 May 05 Shareholder Returns CTLT * MX Pharmaceuticals MX Market 7D 0% 0.2% -3.2% 1Y n/a -25.3% -14.3%
See full shareholder returns
Return vs Market: Insufficient data to determine how CTLT * performed against the MX Market .
Price Volatility Is CTLT *'s price volatile compared to industry and market? CTLT * volatility CTLT * Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 4.1% 10% most volatile stocks in MX Market 6.0% 10% least volatile stocks in MX Market 2.7%
Stable Share Price: CTLT *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine CTLT *'s volatility change over the past year.
About the Company Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.
Show more Catalent, Inc. Fundamentals Summary How do Catalent's earnings and revenue compare to its market cap? CTLT * fundamental statistics Market cap Mex$217.85b Earnings (TTM ) -Mex$20.81b Revenue (TTM ) Mex$87.40b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CTLT * income statement (TTM ) Revenue US$4.38b Cost of Revenue US$3.43b Gross Profit US$953.00m Other Expenses US$2.00b Earnings -US$1.04b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -5.75 Gross Margin 21.75% Net Profit Margin -23.81% Debt/Equity Ratio 126.9%
How did CTLT * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/10/22 11:11 End of Day Share Price 2024/07/25 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Catalent, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Sel Hardy CFRA Equity Research Parth Talsania Equisights
Show 11 more analysts 
